Sunday, September 6, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· March 25, 2026

Arteris Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026

View original at finance.yahoo.com
Arteris Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026 Arteris, Inc. Arteris joins the ranks of Google, Nvidia, Adidas, Walmart, and more in Fast Company’s annual World’s Most Innovative Companies of 2026 list…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Arteris is focused on solving the industry's toughest challenges as AI and chiplet-based architectures continue to evolve, from automating complex network-on-chip creation to enabling secure, scalable data movement for billions of chips

    60% confidence
  • FlexGen enables teams to generate optimized interconnects in a fraction of the time with significantly improved power, performance, and area results

    60% confidence
  • Arteris is focused on solving the industry's toughest challenges as AI and chiplet-based architectures continue to evolve, from automating complex network-on-chip creation to enabling secure, scalable data movement for billions of chips

    60% confidence
  • Arteris is committed to addressing rapid changes in the semiconductor industry and setting new standards for innovation

    60% confidence
  • FlexGen is the industry's first smart network-on-chip (NoC) IP

    60% confidence
  • Arteris is honored to receive Fast Company recognition as it reflects their commitment to addressing rapid changes in the semiconductor industry and setting new standards for innovation

    60% confidence
  • Arteris is committed to addressing rapid changes in the semiconductor industry and setting new standards for what is possible through innovation

    60% confidence
  • FlexGen is the industry's first smart network-on-chip IP

    60% confidence
  • Arteris is committed to addressing rapid changes in the semiconductor industry and setting new standards for what is possible through innovation

    60% confidence
  • FlexGen enables teams to generate optimized interconnects in a fraction of the time with significantly improved power, performance, and area (PPA) results

    60% confidence
  • Arteris is focused on solving the industry's toughest challenges as AI and chiplet-based architectures continue to evolve

    60% confidence
  • FlexGen enables teams to generate optimized interconnects in a fraction of the time with significantly improved power, performance, and area results

    60% confidence
  • Arteris network-on-chip technology has been shipped in more than 4 billion chips and chiplets for major customers and numerous emerging AI innovators globally

    60% confidence
  • Arteris is focused on solving the industry's toughest challenges as AI and chiplet-based architectures continue to evolve, from automating complex network-on-chip creation to enabling secure, scalable data movement

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com